Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-09-01
|
| Series: | BMC Cancer |
| Online Access: | https://doi.org/10.1186/s12885-021-08693-9 |
| _version_ | 1819115686173081600 |
|---|---|
| author | Thomas Powles Toni K. Choueiri Robert J. Motzer Eric Jonasch Sumanta Pal Nizar M. Tannir Sabina Signoretti Rajesh Kaldate Christian Scheffold Evelyn Wang Dana T. Aftab Bernard Escudier Daniel J. George |
| author_facet | Thomas Powles Toni K. Choueiri Robert J. Motzer Eric Jonasch Sumanta Pal Nizar M. Tannir Sabina Signoretti Rajesh Kaldate Christian Scheffold Evelyn Wang Dana T. Aftab Bernard Escudier Daniel J. George |
| author_sort | Thomas Powles |
| collection | DOAJ |
| first_indexed | 2024-12-22T05:05:08Z |
| format | Article |
| id | doaj.art-fb97b853f0ab49559f8e621718cfb4a1 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-22T05:05:08Z |
| publishDate | 2021-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-fb97b853f0ab49559f8e621718cfb4a12022-12-21T18:38:09ZengBMCBMC Cancer1471-24072021-09-012111210.1186/s12885-021-08693-9Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinomaThomas Powles0Toni K. Choueiri1Robert J. Motzer2Eric Jonasch3Sumanta Pal4Nizar M. Tannir5Sabina Signoretti6Rajesh Kaldate7Christian Scheffold8Evelyn Wang9Dana T. Aftab10Bernard Escudier11Daniel J. George12Barts Cancer Institute, Queen Mary University of LondonDana-Farber Cancer CenterMemorial Sloan Kettering Cancer CenterUniversity of Texas MD Anderson Cancer CenterCity of Hope National Medical CenterUniversity of Texas MD Anderson Cancer CenterBrigham and Women’s HospitalExelixis, IncExelixis, IncExelixis, IncExelixis, IncGustave-RoussyDuke Cancer Institutehttps://doi.org/10.1186/s12885-021-08693-9 |
| spellingShingle | Thomas Powles Toni K. Choueiri Robert J. Motzer Eric Jonasch Sumanta Pal Nizar M. Tannir Sabina Signoretti Rajesh Kaldate Christian Scheffold Evelyn Wang Dana T. Aftab Bernard Escudier Daniel J. George Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma BMC Cancer |
| title | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title_full | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title_fullStr | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title_full_unstemmed | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title_short | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title_sort | correction to outcomes based on plasma biomarkers in meteor a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| url | https://doi.org/10.1186/s12885-021-08693-9 |
| work_keys_str_mv | AT thomaspowles correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT tonikchoueiri correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT robertjmotzer correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT ericjonasch correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT sumantapal correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT nizarmtannir correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT sabinasignoretti correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT rajeshkaldate correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT christianscheffold correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT evelynwang correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT danataftab correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT bernardescudier correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT danieljgeorge correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma |